1. Introduction
Triterpenes are secondary metabolites abundantly found in numerous plant species composed of six isoprene units, resulting in a total of 30 carbon atoms in their molecular structure (see
Figure 1A). Among the various triterpenes, pentacyclic triterpenoids constitute approximately 200 different skeletons, showcasing remarkable structural diversity and potent biomedical activity[
1]. Pentacyclic triterpenes that possess either five six-carbon rings (6-6-6-6-6) or four six-carbon rings and one five-carbon ring (6-6-6-6-5) are considered the most important triterpenoids [
2,
3].
Ursane, lupane, and oleanane types are widely distributed within higher plants, including edible plant species. Within the ursane or oleanane type, asiatic acid (AsA), ursolic acid (UrA), and oleanolic acid (OleA) represent a 6-6-6-6-6 structural arrangement. These compounds exhibit very similar structures with only small variations in the substituent groups of the rings.
For instance, AsA possesses an additional hydroxyl group at position 2 and a hydroxymethyl substituent at position 4. On the other hand, OleA differs from UrA in that a methyl substituent has been moved from position 19 to position 20.
Figure 2 provides a visual representation highlighting the differences between these pentacyclic triterpenes.
Interestingly, the lupane-type pentacyclic triterpenes, namely lupeol (Lupe), betulin (Betu), and betulinic acid (BeA), exhibit a 6-6-6-6-5 structural arrangement. The primary distinction among these three compounds lies in the substituent group at position 17. Specifically, Lupe possesses a methyl group, Betu contains a hydroxymethyl group, and BeA features a carboxylic acid group at that position (
Figure 1B). These subtle but specific variations among these six pentacyclic triterpenoids may play a crucial role in their activity across metabolic pathways, especially in cancer[
4].
Cancer is a leading cause of death around the world. Lung cancer is the most common cause of cancer-related deaths. Approximately 85% of all lung cancers are non-small cell lung carcinoma (NSCLC) [
5]. Unfortunately, existing therapies do not cure most NSCLC patients. Even chemotherapy (e.g., cisplatin (CisPt)), the preferred and most effective treatment for lung cancer, only shows a complete response in 30% of individuals with NSCLC [
6]. Additionally, chemoresistance, which results in more aggressive cancer cells, limits the efficacy of chemotherapy. Approximately 10–15% of the patients receiving cisplatin will relapse and invariably develop chemoresistance with an expectance of no longer than a year [
7]. For these reasons, new, less invasive treatments and adjuvant therapies are needed. Pentacyclic triterpenes have demonstrated great potential against NSCLC in vitro and in vivo [
8] and could work to overcome drug resistance mechanisms [
9].
Herein, we investigated the structure-activity-relationship against NSCLC of the six pentacyclic triterpenes AsA, UrA, OleA, Lupe, Betu, and BeA. In order to study this relationship, we determined the impact on cell cycle, DNA, mitochondrial membrane, production of reactive oxygen and nitrogen species (ROS/RNS), and activation of apoptosis and/or autophagy. In addition, we determined the protein expression of the mitogen-activated protein kinase/phosphatidylinositol 3-kinase (MAPK/PI3K), and gene expression of programmed death-ligand 1 (PDL1) and signal transducer and activator of transcription 3 (STAT3), key markers of chemoresistance in NSCLC. This study opens promising perspectives for further research on the role of triterpenoids as therapeutics, which ultimately will contribute to a more rational application in lung cancer therapy.
2. Materials and Methods
2.1. Chemicals and Reagents
Aqueous solutions were prepared with sterile (autoclave conditions: 121 °C and 18 PSI) high quality nanopure water (18.2 MΩ cm resistivity, Thermoscientific® Easypure water purifier).
Asiatic acid, ursolic acid, oleanolic acid, betulin, lupeol, betulinic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA). The cell lines A549 (human lung adenocarcinoma; ATCC CCL-185) and MRC5 (human fibroblast-like cells; ATCC CCL-171) were from the American Type Culture Collection (Manassas, VA, USA). CellTiter 96 aqueous non-radioactive cell proliferation assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent) was from Promega Corporation (Madison, WI, USA). Cell cycle, MAPK/PI3K expression, caspase-3 activation, DNA damage, nitric oxide (NO) and oxidative stress assays were from Luminex Corporation (Austin, TX, USA). All other chemicals were purchased from various suppliers in analytical grade and used without further purification.
2.2. Cell Culture Conditions
Human NSCLC A549 and normal lung MRC5 cell lines were maintained following ATCC protocols. These cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM-high glucose, containing 1% L-glutamine, 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin). Cells were kept in a humidified incubator under 5% CO2 and 95% air at 37 °C. We conducted all the experiments before the cells reached 25 passages. In all the cellular mechanistic experiments, we included CisPt as a control to compare the effects of the six pentacyclic triterpenes with the most used chemotherapy in NSCLC.
2.3. Cell Viability
The 50% inhibitory concentration (IC
50) of some of these triterpenes in A549 NSCLC cells were previously determined by us [
10]. A similar procedure was done to determine the IC
50 of the triterpenes in a normal lung fibroblast cell line (MRC5). In brief, MRC5 cells were seeded into 96-well plates at a density of 1 × 10
5 cells/mL in supplemented DMEM medium. After 24 hours, cells were treated with several concentrations (5, 10, 25, 50, 75, 100 μM) of the triterpenes (BeA, Lupe, Betu, OleA, UrA, AsA), and incubated for 24 hours. Then, 10 uL of the MTS reagent from CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega G5421) was added to each well. Then, we incubated the plate at 37 °C and 5% CO
2 atmosphere for 1-hour. After incubation, absorbance was measured at 492 nm (n = 8) in the microplate reader spectrophotometer (Thermoscientific Multiskan FC). The cell viability was calculated as follows:
% Viability = (sample data − incubation media data) / (untreated cells data − incubation media data) × 100
Cell viability data is presented as mean ± SD of at least three independent experiments. IC50 values were calculated with the GraphPad Prism 9 software (Prism 9; GraphPad by Dotmatics, San Diego, CA, USA) using the dose-response curve. The data were normalized by the non-linear fit of log (drug inhibition) vs. normalized response-variable slope to obtain the best fit IC50 and R-squared values.
2.4. Flow Cytometry Analysis
We used flow cytometry to analyze several cellular mechanistic pathways in A549 cells after incubation with the triterpenes. In general, cells were seeded in a 6-well plate at a density of 1 × 106 cells/mL and incubated for 24 hours in supplemented DMEM. After 24 hours, A549 cells were treated with triterpenes, followed by each manufacturer protocol. All these following experiments were performed in a Muse Cell Analyzer (Muse® Cell Analyzer; EMD Millipore Corporation, Temecula, CA, USA). The concentration of the triterpenes in each assay was selected depending on the cellular concentration necessary to generate the signal in the instrument.
2.4.1. Cell Cycle Arrest
A549 cells were incubated with triterpenes (IC35) for 24 hours. Then, cells were scraped, centrifuged, and then fixed using cold 70% ethanol. Afterward, the fixed cell pellet was incubated with the cell cycle reagent (Luminex MCH100106 kit) for 30 min for immediate measurement.
2.4.2. DNA Damage Induction
A549 cells were incubated with triterpenes (IC50) for 24 hours. Then, A549 cells were scraped and centrifuged. The pellet was suspended in the assay buffer from the Luminex MCH200107 kit. Later, the cell pellet was fixed and permeabilized. Afterward, the antibody cocktail was added and incubated for 30 min. Next, the cell pellet was washed and suspended in fresh assay buffer for measuring.2.4.3 Mitochondrial Polarization
MuseTM MitoPotential Kit (Luminex MCH100110) was used to determine mitochondrial polarization. After the treatment incubation with triterpenes (IC35) for 24 hours, MuseTM MitoPotential working was added and incubated for 20 min at 37°C. Next, MuseTM 7-AAD was added and incubated for 5 minutes at room temperature. Finally, a brief mix was given to each sample before measuring.
2.4.4. Caspase 3 Activation
A549 cells were incubated with triterpenes (IC50) for 24 hours. A549 cells were scraped and centrifuged. The pellet was dissolved in the assay buffer provided by Luminex MCH100108 kit. Then, the fluorescently labeled caspase-3 substrate was added to the dissolved pellet and incubated for 30 min at 37 °C in a 5% CO2 atmosphere for immediate measurement.
2.4.5. Oxidative Stress
Production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) was determined using the Oxidative Stress kit (Luminex MCH100111) and Nitric Oxide kit (MCH100112). After A549 cells were treated with triterpenes (IC50) for 24 hours, the cells were scraped and centrifuged. For ROS, cell pellet was incubated with DHE dye for 1-hour at 37°C. For RNS, cell pellet was incubated with DAX-J2 Orange dye for 30 min at 37°C.
2.4.6. Autophagy activation
Muse® Autophagy LC3-antibody Based Kit (Luminex MCH200109) was used to determine autophagy activation. After A549 cells were treated with triterpenes (IC35) for 24 hours, autophagy reagent A was added for 2~6 hours. Then the cells were detached and centrifuged. The pellet was suspended and incubated for 30 minutes in the autophagy reagent B containing anti-LC3 mouse monoclonal antibody. Finally, the cell pellet was washed and suspended in fresh assay buffer for measuring.
2.4.7. MAPK/PI3K Expression
Muse® P13K/MAPK Dual Pathway Activation Kit (Luminex MCH200108) was used to determine MAPK/PI3K expression. After the treatment incubation with triterpenes (IC35) for 24 hours, A549 cells were scraped, centrifuged, and washed once with 1X PBS. Next, the fixation buffer was incubated for 10 min and then the permeabilization buffer for another 10 min. Both incubations were on ice. Later, the antibody cocktail containing Anti-phospho-Akt and Anti-phospho-ERK1/2 was incubated for 30 min. Afterward, the cell pellet was washed and suspended in fresh assay buffer for measuring.
2.5. RNA extraction and quantitative real-time PCR
A549 cells were seeded into 6-well plates at a density of 1 × 106 cells/mL in supplemented DMEM. Cells were incubated with triterpenes (IC35) for 24 hours. Total RNA was extracted from the cells using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The purity and concentration of RNA were assessed using a NanoDrop spectrophotometer (ThermoScientific). cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's instructions.
Real-time qPCR was performed on a StepOnePlus Real-Time PCR System (Thermo Fisher Scientific) using TaqMan Gene Expression Assays for PDL1 (CD274; Assay ID: Hs01125297_m1), and STAT3 (Assay ID: Hs01047586_g1). Each reaction consisted of 10 ng of cDNA, TaqMan Gene Expression Master Mix (Applied Biosystems), and TaqMan probes. The PCR cycling conditions were as follows: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. The relative gene expression levels were calculated using the ΔΔCt method. GAPDH (Assay ID: Hs02758991_g1) was used as the endogenous control for normalization.
2.6. Statistical Analysis
All experiments were performed at least in triplicate. All data were expressed by plotting values with an average of four to eight measurements for each treatment condition as mean ± SD and analyzed with the software GraphPad Prism 9 (San Diego, CA, USA). Statistical analysis was performed using one-way analysis of variance (ANOVA) to compare the mean value of each treated cells versus the control (untreated cells). The statistical significance defined by the software for P values are: **** < 0.0001, *** from 0.001 to 0.0001, ** from 0.001 to 0.01, * from 0.01 to 0.05, and non-significant (n.s.) ≥ 0.05.
4. Discussion
Triterpenes are known for their wide range of benefits, including their anti-inflammatory, antimicrobial, antiviral, analgesic, anti-tumorigenic, and immunomodulatory characteristics [
11]. Our investigation sought to unravel the interplay between structural variations governing the bioactivity of six lupane, oleanane, and ursane-type pentacyclic triterpenes and their impact on NSCLC cells. This study dive into the underlying mechanistic principles with a particular emphasis on key pathways to induce cells death (i.e., cell cycle arrest, DNA damage, permeability of mitochondrial membrane, activation of caspase 3, and oxidative stress) but also in chemoresistance-related processes (i.e., inhibition of autophagy, MAPK/PI3K, STAT3 and PDL1 expression).
Our experimental results revealed distinct patterns in the response of NSCLC cells to the six pentacyclic triterpenes under scrutiny. In the viability assays, results demonstrated that Lupe has the highest IC
50, OleA the best TI, and BeA has the lowest IC
50 with a TI >1. Normal lung cells such as MRC5 have been considered as cancer associated fibroblasts (CAF) even when they are non-cancerous cells [
12]. This means that an effective therapy must kill both cell lines (NSCLC and CAF) but aggressively to cancerous cells. In this way, BeA showed the lowest IC
50 to kill both cell lines (NSCLC and CAF) but more aggressively to the NSCLC A549 of the six triterpenes. These results suggested that a methyl substituent in lupane-type triterpenes instead of carboxylic acid or hydroxyl can drastically diminish its cytotoxicity. On the other hand, changes in the methyl substituents in OleA (vs UrA) diminished their cytotoxicity in cells but increased the selectivity. Previous studies have found similar IC
50 in the μM range in a 24-hour treatment period for the six selected pentacyclic triterpenes exposed to different cancer cell types [
13,
14,
15,
16,
17,
18]. This highlights the versatility of the use of triterpenes against cancer in different organs and tissues.
Nuclear processes as the cell cycle are important pathways to promote cancer progression. Cell cycle arrest in response to DNA damage is a critical mechanism that helps prevent the propagation of cancer cells and to induce apoptosis [
19]. In this study, all triterpenes produced cell cycle arrest in S-phase and G2/M phase. There are several studies that showed similar results where these triterpenes exhibited S-phase and G2/M phase arrest in myeloma, gastric, breast and lung cancer cells. [
20,
21,
22,
23,
24]. These results suggest that regardless of structural variations, these six pentacyclic triterpenes may trigger cell cycle arrest in these two critical divisions in NSCLC, implying they all may be able to prevent the proliferation of these cancer cells. In addition, only the ursane-type, UrA, and AsA caused DNA damage, implying their other potential targets to kill cancer cells compared to the other four triterpenes. These results revealed that, unlike lupane-type, ursane-type triterpenes might employ DNA damage machinery to induce apoptosis. These results support previous studies that highlight UrA to increase DNA damage and chemosensitizing A549 cells [
25]. In contrast, there are several studies that demonstrated that lupane-type triterpenes are able to cause DNA damage [
26,
27].
Another important pathway is the activation of apoptosis through the mitochondrial response. Disruption of the mitochondrial membrane potential can lead to the release of cytochrome c, which activates caspase 3, initiating apoptosis and then, cell death [
28]. From our results, all the triterpenes induced depolarization of the mitochondrion except Beu. Our findings suggested that a lupane-type triterpene (6-6-6-6-5 ring structure) with a methyl (Lupe) or a carboxylic acid (BeA) substituent can induce high mitochondrial membrane permeability (even higher than CisPt). On the other hand, the ursane-type (UrA and AsA) and OleA, each with a 6-6-6-6-6 ring structural arrangement but varying substituents, induced a mild membrane depolarization.. Most of the studies in the literature showed that pentacyclic triterpenes permeabilize mitochondrion [
23,
27,
29]. Furthermore, all the triterpenes except Lupe activated caspase 3. Interestingly, the triterpenes that less affect the mitochondrial potential greatly increase the caspase activity (and vice versa). This outcome could mean that a greater effect to the mitochondrial potential could cause the inactivation of the complexes in the electron transport chain, e.g., cytochrome c. Another explanation that supports our argument is that membrane depolarization is not a requirement to release cytochrome c from mitochondrion [
30,
31]. The proapoptotic protein Bid can translocate the mitochondrion to induce the release of cytochrome c and caspase-8 can directly activate caspases 3/7 [
32]. This explains why Betu slightly affects the membrane potential but activated a relatively high amount of caspase 3 compared to the other triterpenes. This suggests that caspase-3 activation in Betu-induced apoptosis may not be solely on mitochondrial membrane permeability.
Oxidative stress such as RNS and ROS levels can modulate autophagy. Mild amounts of ROS and RNS promote the autophagic response, while high concentrations inhibit autophagy and promote cell death [
33,
34]. Although all triterpenes produced ROS, comparing to untreated cells, the amount of ROS from BeA, OleA and Lupe are an average of 26.2%, while Betu, AsA and UrA are an average of 10.1%. Thus, BeA, OleA, and Lupe did not activate autophagy because of the high concentration of ROS. On the other hand, Betu, AsA and Top of FormUrA activated the autophagic response by the lower levels of ROS. In the case of RNS, the triterpenes that increased the concentration of RNS are Betu, AsA and UrA. However, compared to untreated cells, the production of RNS for these triterpenes is mild (an average of 7.4%). For this reason, the levels of RNS did not influence the activity of LC3. Based on the structural side of these triterpenes, our results suggested that the skeletal carbon rings structure of the pentacyclic triterpenes is essential in triggering the formation of mitochondrial-derived ROS. Also, they revealed that most of the difference in the six pentacyclic triterpenes structures and their substituents did not inhibit ROS production. A possible explanation is that these triterpenes inhibit complex I or complex III in the electron transport chain. Moreover, the results from the mROS assay correspond with the results from the mitochondrial potential assay, where BeA has the greater induction of RNS and mROS and Betu the lowest. In the case of RNS, our findings suggested that the ursane-type pentacyclic triterpenes are more important in RNS production than lupane-type and oleanane-type. The change in the positions of the methyl groups at the 5
th ring in OleA compared with the ursane-type triterpenes completely abrogated the RNS production. Regarding lupane-type triterpenes, a change of the carboxylic or methyl group for a hydroxyl, such as Betu, drastically improves its effects in RNS production. Numerous studies agreed with our results that triterpenes can induce cell death by the production of ROS, as summarized in the following review [
35]. In contrast, we found few studies of the effect of triterpenes in the production of RNS, where they found the inhibition of NO by BeA and OleA, and the production of NO by UrA [
36,
37] similar to our results. In the case of autophagic response, results in the literature are contradictory. BeA has demonstrated different results depending on the cell type and concentration [
38,
39]. In the same study UrA demonstrated to increase the production of NO, they found to induce autophagy [
37]. In is important to understand that autophagy can suppress tumor development in the early stages, but once the tumor is established, promotes chemotherapy resistance [
40].
MAPK/PI3K has been linked to the upregulation of PDL1, which leads to immune suppression and chemoresistance [
41]. Meanwhile, STAT3-mediated upregulation of PDL1 expression on cancer cells [
41]. In our experiments, only UrA slightly increased the expression of MAPK/PI3K when compared to negative (untreated cells) and positive (CisPt) controls. These results suggested that lupane-type triterpenes with a 6-6-6-6-5 structural arrangement are better in limiting cell progression and survival by MAPK/PI3K independently of the substituents. Regarding the chemoresistance-markers, STAT3 and PDL1, our results revealed that most of the pentacyclic triterpenes suppress these two genes where the chemotherapy CisPt clearly upregulated PDL1. However, BeA was the greater inhibitor of the MAPK/PI3K expression, and PDL1 and STAT3 gene expression in A549. In the literature, we found similar results for MAPK, PI3K, PDL1 and STAT3 after BeA treatment [
42,
43]. UrA also showed to downregulate STAT3 and PDL1 [
44].
In summary, BeA emerge as the triterpenes exerting the most widespread influence on several key pathways to induce mitochondrial-based apoptosis with the lowest IC
50, a TI > 1 and inhibit the chemoresistance-related genes STAT3 and PDL1. Furthermore, we previously demonstrated that BeA synergizes with doxorubicin to increase the effectivity of this drug in A549 cells [
45]. These findings collectively indicate that triterpenes impact different pathways depending on the substituents of their rings. This study strongly supports using pentacyclic triterpenoids in NSCLC and emphasize BeA as the best possible alternative.
Author Contributions
Conceptualization, Y.D.; formal analysis, A.T., C.G., D.P., G.T. S.E., E.V., M.M., and Y.D.; funding acquisition, Y.D.; investigation, Y.D.; methodology, A.T., D.P., G.T. S.E., M.M, E.V., V.M., and Y.D.; project administration, Y.D.; resources, Y.D.; supervision, Y.D.; validation, Y.D.; visualization, Y.D.; writing—original draft, C.G., and Y.D.; writing—review and editing, A.T., and Y.D. All authors have read and agreed to the published version of the manuscript.